Pituitary Carcinoma: A Patient Guide
At a Glance
Pituitary carcinoma, now often called metastatic pituitary neuroendocrine tumor (PitNET), is a rare pituitary tumor that has spread to the brain, spine, or distant organs. A specialist team tailors care, which may include surgery, radiation, temozolomide, and hormone management.
Disclaimer: This guide provides evidence-based information for educational purposes and does not replace the advice of your treating team. If you experience sudden severe headache, new or worsening vision changes, confusion, or collapse, seek emergency medical care immediately.
A diagnosis of Pituitary Carcinoma, which the 2022 WHO classification favors calling a Metastatic Pituitary Neuroendocrine Tumor (Metastatic PitNET), represents a significant shift in your medical journey [1]. Unlike most pituitary tumors, which stay confined to the small area at the base of the brain, this condition is defined by the spread of tumor cells to other parts of the body, such as the brain, spine, or distant organs [2]. It is an exceptionally rare diagnosis, occurring in fewer than 0.2% of all pituitary cases, and often develops many years after an initial pituitary tumor was first identified [3][4].
Because of its rarity, managing this condition requires a level of specialized knowledge that goes beyond standard cancer care. The most effective approach involves a multidisciplinary team of experts—including neuro-oncologists, pituitary neurosurgeons, and specialized endocrinologists—who work together to balance tumor control with hormone management [5][6]. This collaborative effort is essential because the behavior of these tumors is highly individual. There is no single standard combination for every patient; treatment depends on the sites and pace of spread, hormone subtype, symptoms, prior treatment, and patient goals. It often involves an individualized combination of surgical decompression, targeted radiation, and systemic therapies like chemotherapy [7][8].
While the diagnosis is serious, the medical landscape for metastatic PitNET is evolving. When systemic treatment is indicated for aggressive or progressive disease, the oral chemotherapy drug temozolomide is guideline-supported first-line chemotherapy, and newer investigational options such as immunotherapy and targeted radiation are being explored in specialized centers [5][9]. Navigating this path involves consistent monitoring through imaging and blood work, but it also offers opportunities for you to advocate for the most advanced care available. By partnering with a dedicated team of specialists, you can ensure that your treatment plan is as unique as your diagnosis, focusing on both controlling the disease and maintaining your quality of life [10].
In this guide
6 chapters
Understanding Pituitary Carcinoma (Metastatic PitNET)
Learn what pituitary carcinoma, now called metastatic PitNET, means, how spread is confirmed, treatment options, and why specialized team care matters.
The Biology and Pathology of Your Diagnosis
Learn how pituitary carcinoma pathology reports use Ki-67, mitotic count, p53, hormone lineage, and MGMT to assess tumor behavior and guide treatment choices.
Recognizing Emergencies and Warning Signs
Learn the emergency warning signs of pituitary carcinoma, including apoplexy, adrenal crisis, vision changes, blood clots, and when to seek urgent care.
Treatment Pathways and Standard of Care
Learn how pituitary carcinoma is treated with surgery, radiation, temozolomide, and hormone control, including adrenalectomy for Cushing’s and clinical trials.
Building Your Care Team and First Visit Prep
Learn how to prepare for pituitary carcinoma care: choose a specialized team, gather scans and pathology records, and ask key questions at your first visit.
Ongoing Care, Monitoring, and Support
Learn how metastatic PitNET (pituitary carcinoma) is monitored with MRI and hormone tests, how treatment response shapes prognosis, and ways to manage scanxiety.
Common questions in this guide
What is pituitary carcinoma, and what does metastatic PitNET mean?
How rare is metastatic PitNET, and when can it appear?
What specialists should be involved in treating metastatic PitNET?
What treatments are used for pituitary carcinoma?
Which symptoms mean I should seek emergency care?
How can I choose a care team for metastatic PitNET?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Does our hospital have a specialized multidisciplinary tumor board that reviews cases of metastatic pituitary tumors?
- 2.Given the rarity of my diagnosis, how many patients with metastatic PitNET has this team managed in the last few years?
- 3.Who is the primary point of contact for coordinating my care between neurosurgery, oncology, and endocrinology?
- 4.What are our main goals for the next three to six months of treatment?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (10)
- 1
Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL, Mete O, Perry A, Osamura RY
Endocrine pathology 2022; (33(1)):6-26 doi:10.1007/s12022-022-09703-7.
PMID: 35291028 - 2
Pituitary carcinoma: reclassification and implications in the NET schema.
Asa SL, Ezzat S
Endocrine oncology (Bristol, England) 2022; (2(1)):R14-R23 doi:10.1530/EO-22-0041.
PMID: 37435449 - 3
Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review.
Yoo F, Kuan EC, Heaney AP, et al.
Pituitary 2018; (21(3)):290-301 doi:10.1007/s11102-018-0872-8.
PMID: 29404894 - 4
Role of Surgery in the Multimodal Treatment of Pituitary Carcinoma: A Retrospective Single-Institution Case Series.
Faraj CA, Tran M, Ferguson SD, et al.
Cancers 2026; (18(13)) doi:10.3390/cancers18132064.
PMID: 42449609 - 5
European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas.
Raverot G, Burman P, McCormack A, et al.
European journal of endocrinology 2018; (178(1)):G1-G24.
PMID: 29046323 - 6
Aggressive and Metastatic Pituitary Neuroendocrine Tumors: Therapeutic Management and Off-Label Drug Use.
Iglesias P
Journal of clinical medicine 2023; (13(1)) doi:10.3390/jcm13010116.
PMID: 38202123 - 7
Delayed Craniospinal Metastasis of Aggressive Nonfunctioning Pituitary Adenomas as Pituitary Carcinomas.
Raghu ALB, Everson MC, Helal A, et al.
Journal of neurological surgery. Part B, Skull base 2022; (83(Suppl 2)):e253-e259 doi:10.1055/s-0041-1725024.
PMID: 35832993 - 8
Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain.
Lamas C, Cámara R, Fajardo C, et al.
Frontiers in endocrinology 2023; (14()):1204206 doi:10.3389/fendo.2023.1204206.
PMID: 37720528 - 9
Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study.
Majd N, Waguespack SG, Janku F, et al.
Journal for immunotherapy of cancer 2020; (8(2)) doi:10.1136/jitc-2020-001532.
PMID: 33427689 - 10
Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas.
Raverot G, Burman P, Abreu AP, et al.
European journal of endocrinology 2025; (192(6)):R45-R78 doi:10.1093/ejendo/lvaf100.
PMID: 40506054
This page about metastatic pituitary neuroendocrine tumors is for informational purposes only and does not constitute medical advice or replace your treating team’s guidance. Seek emergency care for sudden severe headache, new or worsening vision changes, confusion, or collapse.
Get notified when new evidence is published on Pituitary carcinoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.